AstraZeneca's Phase 3 Trial Shows Significant Results in Patients With Hypoparathyroidism

MT Newswires Live05-12

AstraZeneca (AZN) said Tuesday phase 3 trial results showed that its investigational drug eneboparatide significantly normalized serum calcium and achieved independence from active vitamin D and oral calcium supplements in adults with hypoparathyroidism.

The investigational drug met its composite primary endpoint as 31.1% of treated patients achieved normalization of albumin-adjusted serum calcium levels and independence from oral supplements at week 24, compared with 5.9% of the patients in the placebo group, the company said.

The trial also met all key secondary endpoints, including the normalization of urinary calcium excretion in patients with hypercalciuria at baseline, according to a statement.

Eneboparatide was well tolerated with a consistent overall safety profile over 52 weeks of treatment, the statement said.

Price: 183.52, Change: +1.65, Percent Change: +0.91

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment